Keyphrases
Aberrations
100%
Acute Lymphoblastic Leukemia Cells
16%
BCP-ALL
16%
BCR-ABL1-like
50%
Bother
16%
Childhood B-cell Precursor Acute Lymphoblastic Leukemia
100%
Clinical Integration
16%
Clinical Outcomes
16%
Cytokine Receptor
16%
Induced Resistance
16%
Inhibitor Therapy
16%
Inhibitor Treatment
16%
JAK Inhibition
16%
JAK Inhibitors
50%
JAK2 mutation
33%
JAK2 Signaling
16%
Janus Kinase 2 (JAK2)
100%
Microenvironment
16%
Momelotinib
16%
Paediatric B-cell Precursor Acute Lymphoblastic Leukaemia
33%
Poor Prognostic
16%
Precision Medicine
16%
Primary B Cells
16%
Prognostic Subtype
16%
Receptor Activation
16%
Ruxolitinib
16%
Sentinel
16%
Survival Pathways
16%
Translocated
16%
Medicine and Dentistry
Acute Lymphoblastic Leukemia
100%
B Cell
100%
Cytokine Receptor
11%
Induced Resistance
11%
Janus Kinase
100%
Janus Kinase Inhibitor
33%
Leukemia Cell
11%
Momelotinib
11%
Pediatrics
22%
Personalized Medicine
11%
Precursor
100%
Ruxolitinib
11%
Thymic Stromal Lymphopoietin
11%
Biochemistry, Genetics and Molecular Biology
B Cell
100%
Cytogenetics
11%
Cytokine Receptor
11%
Induced Resistance
11%
Janus Kinase
100%
Janus Kinase Inhibitor
33%
Precursor
100%
Ruxolitinib
11%
Thymic Stromal Lymphopoietin
11%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Lymphoblastic Leukemia
100%
Cytokine Receptor
11%
Janus Kinase
100%
Janus Kinase Inhibitor
33%
Momelotinib
11%
Ruxolitinib
11%
Thymic Stromal Lymphopoietin
11%